To compare the sensitivity of CD138++ and CD138low cells to different anti-myeloma drugs we sorted both subpopulations from the RPMI-8226 cell line and incubated the two subpopulations in the absence (control) or presence of bortezomib, melphalan or doxorubicin. The gene discussed is SDC1; the disease is plasma cell myeloma.